Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Services Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Small Molecule CDMO
1.2.3 Macro-molecular CDMO
1.3 Market by Application
1.3.1 Global Peptide CDMO Services Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Clinical Treatment
1.3.3 Medical Research
1.3.4 Commercial Production
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Services Market Perspective (2018-2033)
2.2 Peptide CDMO Services Growth Trends by Region
2.2.1 Global Peptide CDMO Services Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Peptide CDMO Services Historic Market Size by Region (2018-2023)
2.2.3 Peptide CDMO Services Forecasted Market Size by Region (2024-2033)
2.3 Peptide CDMO Services Market Dynamics
2.3.1 Peptide CDMO Services Industry Trends
2.3.2 Peptide CDMO Services Market Drivers
2.3.3 Peptide CDMO Services Market Challenges
2.3.4 Peptide CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide CDMO Services Players by Revenue
3.1.1 Global Top Peptide CDMO Services Players by Revenue (2018-2023)
3.1.2 Global Peptide CDMO Services Revenue Market Share by Players (2018-2023)
3.2 Global Peptide CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide CDMO Services Revenue
3.4 Global Peptide CDMO Services Market Concentration Ratio
3.4.1 Global Peptide CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Services Revenue in 2022
3.5 Peptide CDMO Services Key Players Head office and Area Served
3.6 Key Players Peptide CDMO Services Product Solution and Service
3.7 Date of Enter into Peptide CDMO Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide CDMO Services Breakdown Data by Type
4.1 Global Peptide CDMO Services Historic Market Size by Type (2018-2023)
4.2 Global Peptide CDMO Services Forecasted Market Size by Type (2024-2033)
5 Peptide CDMO Services Breakdown Data by Application
5.1 Global Peptide CDMO Services Historic Market Size by Application (2018-2023)
5.2 Global Peptide CDMO Services Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Peptide CDMO Services Market Size (2018-2033)
6.2 North America Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Peptide CDMO Services Market Size by Country (2018-2023)
6.4 North America Peptide CDMO Services Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide CDMO Services Market Size (2018-2033)
7.2 Europe Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Peptide CDMO Services Market Size by Country (2018-2023)
7.4 Europe Peptide CDMO Services Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide CDMO Services Market Size (2018-2033)
8.2 Asia-Pacific Peptide CDMO Services Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Peptide CDMO Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Peptide CDMO Services Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide CDMO Services Market Size (2018-2033)
9.2 Latin America Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Peptide CDMO Services Market Size by Country (2018-2023)
9.4 Latin America Peptide CDMO Services Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide CDMO Services Market Size (2018-2033)
10.2 Middle East & Africa Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Peptide CDMO Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Peptide CDMO Services Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Incyte
11.1.1 Incyte Company Detail
11.1.2 Incyte Business Overview
11.1.3 Incyte Peptide CDMO Services Introduction
11.1.4 Incyte Revenue in Peptide CDMO Services Business (2018-2023)
11.1.5 Incyte Recent Development
11.2 Gliead
11.2.1 Gliead Company Detail
11.2.2 Gliead Business Overview
11.2.3 Gliead Peptide CDMO Services Introduction
11.2.4 Gliead Revenue in Peptide CDMO Services Business (2018-2023)
11.2.5 Gliead Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Peptide CDMO Services Introduction
11.3.4 Boehringer Ingelheim Revenue in Peptide CDMO Services Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Peptide CDMO Services Introduction
11.4.4 Vertex Revenue in Peptide CDMO Services Business (2018-2023)
11.4.5 Vertex Recent Development
11.5 Mirati Therapeutics
11.5.1 Mirati Therapeutics Company Detail
11.5.2 Mirati Therapeutics Business Overview
11.5.3 Mirati Therapeutics Peptide CDMO Services Introduction
11.5.4 Mirati Therapeutics Revenue in Peptide CDMO Services Business (2018-2023)
11.5.5 Mirati Therapeutics Recent Development
11.6 AMPAC
11.6.1 AMPAC Company Detail
11.6.2 AMPAC Business Overview
11.6.3 AMPAC Peptide CDMO Services Introduction
11.6.4 AMPAC Revenue in Peptide CDMO Services Business (2018-2023)
11.6.5 AMPAC Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Peptide CDMO Services Introduction
11.7.4 Pfizer Revenue in Peptide CDMO Services Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Polypeptide
11.8.1 Polypeptide Company Detail
11.8.2 Polypeptide Business Overview
11.8.3 Polypeptide Peptide CDMO Services Introduction
11.8.4 Polypeptide Revenue in Peptide CDMO Services Business (2018-2023)
11.8.5 Polypeptide Recent Development
11.9 Bachem
11.9.1 Bachem Company Detail
11.9.2 Bachem Business Overview
11.9.3 Bachem Peptide CDMO Services Introduction
11.9.4 Bachem Revenue in Peptide CDMO Services Business (2018-2023)
11.9.5 Bachem Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Peptide CDMO Services Introduction
11.10.4 Merck Revenue in Peptide CDMO Services Business (2018-2023)
11.10.5 Merck Recent Development
11.11 Asymchem
11.11.1 Asymchem Company Detail
11.11.2 Asymchem Business Overview
11.11.3 Asymchem Peptide CDMO Services Introduction
11.11.4 Asymchem Revenue in Peptide CDMO Services Business (2018-2023)
11.11.5 Asymchem Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Sinopep
11.13.1 Sinopep Company Detail
11.13.2 Sinopep Business Overview
11.13.3 Sinopep Peptide CDMO Services Introduction
11.13.4 Sinopep Revenue in Peptide CDMO Services Business (2018-2023)
11.13.5 Sinopep Recent Development
11.14 Frontier Biotechnologies
11.14.1 Frontier Biotechnologies Company Detail
11.14.2 Frontier Biotechnologies Business Overview
11.14.3 Frontier Biotechnologies Peptide CDMO Services Introduction
11.14.4 Frontier Biotechnologies Revenue in Peptide CDMO Services Business (2018-2023)
11.14.5 Frontier Biotechnologies Recent Development
11.15 JYMed
11.15.1 JYMed Company Detail
11.15.2 JYMed Business Overview
11.15.3 JYMed Peptide CDMO Services Introduction
11.15.4 JYMed Revenue in Peptide CDMO Services Business (2018-2023)
11.15.5 JYMed Recent Development
11.16 Chengdu Shengnuo Biotechnology
11.16.1 Chengdu Shengnuo Biotechnology Company Detail
11.16.2 Chengdu Shengnuo Biotechnology Business Overview
11.16.3 Chengdu Shengnuo Biotechnology Peptide CDMO Services Introduction
11.16.4 Chengdu Shengnuo Biotechnology Revenue in Peptide CDMO Services Business (2018-2023)
11.16.5 Chengdu Shengnuo Biotechnology Recent Development
11.17 Shanghai Soho-Yiming Pharmaceuticals
11.17.1 Shanghai Soho-Yiming Pharmaceuticals Company Detail
11.17.2 Shanghai Soho-Yiming Pharmaceuticals Business Overview
11.17.3 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Introduction
11.17.4 Shanghai Soho-Yiming Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023)
11.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Development
11.18 Chinese Peptide Company
11.18.1 Chinese Peptide Company Company Detail
11.18.2 Chinese Peptide Company Business Overview
11.18.3 Chinese Peptide Company Peptide CDMO Services Introduction
11.18.4 Chinese Peptide Company Revenue in Peptide CDMO Services Business (2018-2023)
11.18.5 Chinese Peptide Company Recent Development
11.19 Ambio Pharmaceuticals
11.19.1 Ambio Pharmaceuticals Company Detail
11.19.2 Ambio Pharmaceuticals Business Overview
11.19.3 Ambio Pharmaceuticals Peptide CDMO Services Introduction
11.19.4 Ambio Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023)
11.19.5 Ambio Pharmaceuticals Recent Development
11.20 Zhejiang Peptites Biotech
11.20.1 Zhejiang Peptites Biotech Company Detail
11.20.2 Zhejiang Peptites Biotech Business Overview
11.20.3 Zhejiang Peptites Biotech Peptide CDMO Services Introduction
11.20.4 Zhejiang Peptites Biotech Revenue in Peptide CDMO Services Business (2018-2023)
11.20.5 Zhejiang Peptites Biotech Recent Development
11.21 STA Pharmaceutical
11.21.1 STA Pharmaceutical Company Detail
11.21.2 STA Pharmaceutical Business Overview
11.21.3 STA Pharmaceutical Peptide CDMO Services Introduction
11.21.4 STA Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023)
11.21.5 STA Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Peptide CDMO Services Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Small Molecule CDMO
Table 3. Key Players of Macro-molecular CDMO
Table 4. Global Peptide CDMO Services Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Peptide CDMO Services Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Peptide CDMO Services Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Peptide CDMO Services Market Share by Region (2018-2023)
Table 8. Global Peptide CDMO Services Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Peptide CDMO Services Market Share by Region (2024-2033)
Table 10. Peptide CDMO Services Market Trends
Table 11. Peptide CDMO Services Market Drivers
Table 12. Peptide CDMO Services Market Challenges
Table 13. Peptide CDMO Services Market Restraints
Table 14. Global Peptide CDMO Services Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Peptide CDMO Services Market Share by Players (2018-2023)
Table 16. Global Top Peptide CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Services as of 2022)
Table 17. Ranking of Global Top Peptide CDMO Services Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Peptide CDMO Services Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Peptide CDMO Services Product Solution and Service
Table 21. Date of Enter into Peptide CDMO Services Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide CDMO Services Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Peptide CDMO Services Revenue Market Share by Type (2018-2023)
Table 25. Global Peptide CDMO Services Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Peptide CDMO Services Revenue Market Share by Type (2024-2033)
Table 27. Global Peptide CDMO Services Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Peptide CDMO Services Revenue Market Share by Application (2018-2023)
Table 29. Global Peptide CDMO Services Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Peptide CDMO Services Revenue Market Share by Application (2024-2033)
Table 31. North America Peptide CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Peptide CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Peptide CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Peptide CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Peptide CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Peptide CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Peptide CDMO Services Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Peptide CDMO Services Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Peptide CDMO Services Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Peptide CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Peptide CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Peptide CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Peptide CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Peptide CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Peptide CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 46. Incyte Company Detail
Table 47. Incyte Business Overview
Table 48. Incyte Peptide CDMO Services Product
Table 49. Incyte Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 50. Incyte Recent Development
Table 51. Gliead Company Detail
Table 52. Gliead Business Overview
Table 53. Gliead Peptide CDMO Services Product
Table 54. Gliead Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 55. Gliead Recent Development
Table 56. Boehringer Ingelheim Company Detail
Table 57. Boehringer Ingelheim Business Overview
Table 58. Boehringer Ingelheim Peptide CDMO Services Product
Table 59. Boehringer Ingelheim Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 60. Boehringer Ingelheim Recent Development
Table 61. Vertex Company Detail
Table 62. Vertex Business Overview
Table 63. Vertex Peptide CDMO Services Product
Table 64. Vertex Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 65. Vertex Recent Development
Table 66. Mirati Therapeutics Company Detail
Table 67. Mirati Therapeutics Business Overview
Table 68. Mirati Therapeutics Peptide CDMO Services Product
Table 69. Mirati Therapeutics Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 70. Mirati Therapeutics Recent Development
Table 71. AMPAC Company Detail
Table 72. AMPAC Business Overview
Table 73. AMPAC Peptide CDMO Services Product
Table 74. AMPAC Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 75. AMPAC Recent Development
Table 76. Pfizer Company Detail
Table 77. Pfizer Business Overview
Table 78. Pfizer Peptide CDMO Services Product
Table 79. Pfizer Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Polypeptide Company Detail
Table 82. Polypeptide Business Overview
Table 83. Polypeptide Peptide CDMO Services Product
Table 84. Polypeptide Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 85. Polypeptide Recent Development
Table 86. Bachem Company Detail
Table 87. Bachem Business Overview
Table 88. Bachem Peptide CDMO Services Product
Table 89. Bachem Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 90. Bachem Recent Development
Table 91. Merck Company Detail
Table 92. Merck Business Overview
Table 93. Merck Peptide CDMO Services Product
Table 94. Merck Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 95. Merck Recent Development
Table 96. Asymchem Company Detail
Table 97. Asymchem Business Overview
Table 98. Asymchem Peptide CDMO Services Product
Table 99. Asymchem Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 100. Asymchem Recent Development
Table 101. Zhejiang Jiuzhou Pharmaceutical Company Detail
Table 102. Zhejiang Jiuzhou Pharmaceutical Business Overview
Table 103. Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Product
Table 104. Zhejiang Jiuzhou Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 105. Zhejiang Jiuzhou Pharmaceutical Recent Development
Table 106. Sinopep Company Detail
Table 107. Sinopep Business Overview
Table 108. Sinopep Peptide CDMO Services Product
Table 109. Sinopep Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 110. Sinopep Recent Development
Table 111. Frontier Biotechnologies Company Detail
Table 112. Frontier Biotechnologies Business Overview
Table 113. Frontier Biotechnologies Peptide CDMO Services Product
Table 114. Frontier Biotechnologies Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 115. Frontier Biotechnologies Recent Development
Table 116. JYMed Company Detail
Table 117. JYMed Business Overview
Table 118. JYMed Peptide CDMO Services Product
Table 119. JYMed Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 120. JYMed Recent Development
Table 121. Chengdu Shengnuo Biotechnology Company Detail
Table 122. Chengdu Shengnuo Biotechnology Business Overview
Table 123. Chengdu Shengnuo Biotechnology Peptide CDMO Services Product
Table 124. Chengdu Shengnuo Biotechnology Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 125. Chengdu Shengnuo Biotechnology Recent Development
Table 126. Shanghai Soho-Yiming Pharmaceuticals Company Detail
Table 127. Shanghai Soho-Yiming Pharmaceuticals Business Overview
Table 128. Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Product
Table 129. Shanghai Soho-Yiming Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 130. Shanghai Soho-Yiming Pharmaceuticals Recent Development
Table 131. Chinese Peptide Company Company Detail
Table 132. Chinese Peptide Company Business Overview
Table 133. Chinese Peptide Company Peptide CDMO Services Product
Table 134. Chinese Peptide Company Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 135. Chinese Peptide Company Recent Development
Table 136. Ambio Pharmaceuticals Company Detail
Table 137. Ambio Pharmaceuticals Business Overview
Table 138. Ambio Pharmaceuticals Peptide CDMO Services Product
Table 139. Ambio Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 140. Ambio Pharmaceuticals Recent Development
Table 141. Zhejiang Peptites Biotech Company Detail
Table 142. Zhejiang Peptites Biotech Business Overview
Table 143. Zhejiang Peptites Biotech Peptide CDMO Services Product
Table 144. Zhejiang Peptites Biotech Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 145. Zhejiang Peptites Biotech Recent Development
Table 146. STA Pharmaceutical Company Detail
Table 147. STA Pharmaceutical Business Overview
Table 148. STA Pharmaceutical Peptide CDMO Services Product
Table 149. STA Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023) & (US$ Million)
Table 150. STA Pharmaceutical Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide CDMO Services Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Peptide CDMO Services Market Share by Type: 2022 VS 2033
Figure 3. Small Molecule CDMO Features
Figure 4. Macro-molecular CDMO Features
Figure 5. Global Peptide CDMO Services Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Peptide CDMO Services Market Share by Application: 2022 VS 2033
Figure 7. Clinical Treatment Case Studies
Figure 8. Medical Research Case Studies
Figure 9. Commercial Production Case Studies
Figure 10. Peptide CDMO Services Report Years Considered
Figure 11. Global Peptide CDMO Services Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Peptide CDMO Services Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Peptide CDMO Services Market Share by Region: 2022 VS 2033
Figure 14. Global Peptide CDMO Services Market Share by Players in 2022
Figure 15. Global Top Peptide CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Services as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Peptide CDMO Services Revenue in 2022
Figure 17. North America Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Peptide CDMO Services Market Share by Country (2018-2033)
Figure 19. United States Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Peptide CDMO Services Market Share by Country (2018-2033)
Figure 23. Germany Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Peptide CDMO Services Market Share by Region (2018-2033)
Figure 31. China Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Peptide CDMO Services Market Share by Country (2018-2033)
Figure 39. Mexico Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Peptide CDMO Services Market Share by Country (2018-2033)
Figure 43. Turkey Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Peptide CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Incyte Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 46. Gliead Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 47. Boehringer Ingelheim Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 48. Vertex Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 49. Mirati Therapeutics Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 50. AMPAC Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 51. Pfizer Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 52. Polypeptide Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 53. Bachem Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 54. Merck Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 55. Asymchem Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 56. Zhejiang Jiuzhou Pharmaceutical Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 57. Sinopep Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 58. Frontier Biotechnologies Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 59. JYMed Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 60. Chengdu Shengnuo Biotechnology Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 61. Shanghai Soho-Yiming Pharmaceuticals Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 62. Chinese Peptide Company Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 63. Ambio Pharmaceuticals Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 64. Zhejiang Peptites Biotech Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 65. STA Pharmaceutical Revenue Growth Rate in Peptide CDMO Services Business (2018-2023)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed